TheraGenetics Joins Kings College London in Alzheimer's Drug PGx Study | GenomeWeb
NEW YORK (GenomeWeb News) – Diagnostics company TheraGenetics will conduct a pharmacogenetic study along with King’s College London of Alzheimer’s patients who have been treated with cholinesterase inhibitors in the larger AddNeuroMed study.
 
TheraGenetics has been searching for genetic markers related to central nervous system disorders that could be used to develop diagnostic tests for Alzheimer’s disease, schizophrenia, depression, bipolar disorder, and attention deficit hyperactivity disorder.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.